{"pmid":32479865,"pmcid":"PMC7258847","title":"Lack of Antiviral Activity of Darunavir against SARS-CoV-2.","text":["Lack of Antiviral Activity of Darunavir against SARS-CoV-2.","OBJECTIVES: Given the high need and the absence of specific antivirals for treatment of COVID-19 (the disease caused by severe acute respiratory syndrome-associated coronavirus-2 [SARS-CoV-2]), human immunodeficiency virus (HIV) protease inhibitors are being considered as therapeutic alternatives. METHODS: Prezcobix/Rezolsta is a fixed-dose combination of 800mg of the HIV protease inhibitor darunavir (DRV) and 150mg cobicistat, a CYP3A4 inhibitor, which is indicated in combination with other antiretroviral agents for the treatment of HIV infection. There are currently no definitive data on the safety and efficacy of DRV/cobicistat for treatment of COVID-19. The in vitro antiviral activity of darunavir against a clinical isolate from a patient infected with SARS-CoV-2 was assessed. RESULTS: DRV showed no activity against SARS-CoV-2 at clinically relevant concentrations (EC50 >100muM). Remdesivir, used as a positive control, showed potent antiviral activity (EC50=0.38muM). CONCLUSIONS: Overall, the data do not support the use of DRV for treatment of COVID-19.","Int J Infect Dis","De Meyer, Sandra","Bojkova, Denisa","Cinatl, Jindrich","Van Damme, Ellen","Meng, Christophe Buyck","Van Loock, Marnix","Woodfall, Brian","Ciesek, Sandra","32479865"],"abstract":["OBJECTIVES: Given the high need and the absence of specific antivirals for treatment of COVID-19 (the disease caused by severe acute respiratory syndrome-associated coronavirus-2 [SARS-CoV-2]), human immunodeficiency virus (HIV) protease inhibitors are being considered as therapeutic alternatives. METHODS: Prezcobix/Rezolsta is a fixed-dose combination of 800mg of the HIV protease inhibitor darunavir (DRV) and 150mg cobicistat, a CYP3A4 inhibitor, which is indicated in combination with other antiretroviral agents for the treatment of HIV infection. There are currently no definitive data on the safety and efficacy of DRV/cobicistat for treatment of COVID-19. The in vitro antiviral activity of darunavir against a clinical isolate from a patient infected with SARS-CoV-2 was assessed. RESULTS: DRV showed no activity against SARS-CoV-2 at clinically relevant concentrations (EC50 >100muM). Remdesivir, used as a positive control, showed potent antiviral activity (EC50=0.38muM). CONCLUSIONS: Overall, the data do not support the use of DRV for treatment of COVID-19."],"journal":"Int J Infect Dis","authors":["De Meyer, Sandra","Bojkova, Denisa","Cinatl, Jindrich","Van Damme, Ellen","Meng, Christophe Buyck","Van Loock, Marnix","Woodfall, Brian","Ciesek, Sandra"],"date":"2020-06-02T11:00:00Z","year":2020,"_id":"32479865","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.ijid.2020.05.085","keywords":["covid-19","darunavir","sars-cov-2","in vitro"],"e_drugs":["remdesivir","Cobicistat","Darunavir"],"topics":["Treatment"],"weight":1,"_version_":1668532089553682432,"score":9.490897,"similar":[{"pmid":32292805,"pmcid":"PMC7152873","title":"Data on the stability of darunavir/cobicistat suspension after tablet manipulation.","text":["Data on the stability of darunavir/cobicistat suspension after tablet manipulation.","The COVID-19 outbreak is now one of the most critical crises to manage for most of the national healthcare systems in the world. In the absence of authorised pharmacological treatments, many antiretrovirals, including darunavir/cobicistat fixed combination, were used off-label in the hospital wards as life-treating medicines for COVID-19 patients. Unfortunately, for most of them, the drug products available on the market are not designed to be administered by a nasogastric tube to inpatients of intensive care units. Therefore, their manipulation, even if it can strongly affect the product quality, is necessary for the preparation of suspension to meet patients' need. In this situation, it is urgent to provide data and guidance to support hospital pharmacist and clinicians in their activity. The data in this article indicate that darunavir/cobicistat suspensions compounded by pharmacists using as active ingredient a commercially available tablet can be stable at least for one week.","Data Brief","Zanon, D","Manca, A","De Nicolo, A","D'Avolio, A","Musazzi, U M","Cilurzo, F","Maximova, N","Tomasello, C","Minghetti, P","32292805"],"abstract":["The COVID-19 outbreak is now one of the most critical crises to manage for most of the national healthcare systems in the world. In the absence of authorised pharmacological treatments, many antiretrovirals, including darunavir/cobicistat fixed combination, were used off-label in the hospital wards as life-treating medicines for COVID-19 patients. Unfortunately, for most of them, the drug products available on the market are not designed to be administered by a nasogastric tube to inpatients of intensive care units. Therefore, their manipulation, even if it can strongly affect the product quality, is necessary for the preparation of suspension to meet patients' need. In this situation, it is urgent to provide data and guidance to support hospital pharmacist and clinicians in their activity. The data in this article indicate that darunavir/cobicistat suspensions compounded by pharmacists using as active ingredient a commercially available tablet can be stable at least for one week."],"journal":"Data Brief","authors":["Zanon, D","Manca, A","De Nicolo, A","D'Avolio, A","Musazzi, U M","Cilurzo, F","Maximova, N","Tomasello, C","Minghetti, P"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32292805","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.dib.2020.105552","keywords":["covid-19","cobicistat","darunavir","medicament manipulation","nasogastric tube"],"e_drugs":["Cobicistat","Darunavir"],"topics":["Treatment"],"weight":1,"_version_":1666138494502699009,"score":371.48502},{"pmid":32429580,"title":"Comparative Antiviral Activity of Remdesivir and Anti-HIV Nucleoside Analogs Against Human Coronavirus 229E (HCoV-229E).","text":["Comparative Antiviral Activity of Remdesivir and Anti-HIV Nucleoside Analogs Against Human Coronavirus 229E (HCoV-229E).","Remdesivir is a nucleotide prodrug that is currently undergoing extensive clinical trials for the treatment of COVID-19. The prodrug is metabolized to its active triphosphate form and interferes with the action of RNA-dependent RNA polymerase of SARS-COV-2. Herein, we report the antiviral activity of remdesivir against human coronavirus 229E (HCoV-229E) compared to known anti-HIV agents. These agents included tenofovir (TFV), 4'-ethynyl-2-fluoro-2'-deoxyadenosine (EFdA), alovudine (FLT), lamivudine (3TC), and emtricitabine (FTC), known as nucleoside reverse-transcriptase inhibitors (NRTIs), and a number of 5'-O-fatty acylated anti-HIV nucleoside conjugates. The anti-HIV nucleosides interfere with HIV RNA-dependent DNA polymerase and/or act as chain terminators. Normal human fibroblast lung cells (MRC-5) were used to determine the cytotoxicity of the compounds. The study revealed that remdesivir exhibited an EC50 value of 0.07 microM against HCoV-229E with TC50 of > 2.00 microM against MRC-5 cells. Parent NRTIs were found to be inactive against (HCoV-229E) at tested concentrations. Among all the NRTIs and 5'-O-fatty acyl conjugates of NRTIs, 5'-O-tetradecanoyl ester conjugate of FTC showed modest activity with EC50 and TC50 values of 72.8 microM and 87.5 microM, respectively. These data can be used for the design of potential compounds against other coronaviruses.","Molecules","Parang, Keykavous","El-Sayed, Naglaa Salem","Kazeminy, Assad J","Tiwari, Rakesh K","32429580"],"abstract":["Remdesivir is a nucleotide prodrug that is currently undergoing extensive clinical trials for the treatment of COVID-19. The prodrug is metabolized to its active triphosphate form and interferes with the action of RNA-dependent RNA polymerase of SARS-COV-2. Herein, we report the antiviral activity of remdesivir against human coronavirus 229E (HCoV-229E) compared to known anti-HIV agents. These agents included tenofovir (TFV), 4'-ethynyl-2-fluoro-2'-deoxyadenosine (EFdA), alovudine (FLT), lamivudine (3TC), and emtricitabine (FTC), known as nucleoside reverse-transcriptase inhibitors (NRTIs), and a number of 5'-O-fatty acylated anti-HIV nucleoside conjugates. The anti-HIV nucleosides interfere with HIV RNA-dependent DNA polymerase and/or act as chain terminators. Normal human fibroblast lung cells (MRC-5) were used to determine the cytotoxicity of the compounds. The study revealed that remdesivir exhibited an EC50 value of 0.07 microM against HCoV-229E with TC50 of > 2.00 microM against MRC-5 cells. Parent NRTIs were found to be inactive against (HCoV-229E) at tested concentrations. Among all the NRTIs and 5'-O-fatty acyl conjugates of NRTIs, 5'-O-tetradecanoyl ester conjugate of FTC showed modest activity with EC50 and TC50 values of 72.8 microM and 87.5 microM, respectively. These data can be used for the design of potential compounds against other coronaviruses."],"journal":"Molecules","authors":["Parang, Keykavous","El-Sayed, Naglaa Salem","Kazeminy, Assad J","Tiwari, Rakesh K"],"date":"2020-05-21T11:00:00Z","year":2020,"_id":"32429580","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.3390/molecules25102343","keywords":["hcov-229e","nrtis","rna polymerase","sars-cov-2","antiviral","remdesivir"],"e_drugs":["Tenofovir","remdesivir","triphosphoric acid","4'-ethynyl-2-fluoro-2'-deoxyadenosine","Emtricitabine","alovudine","Lamivudine","Nucleosides"],"topics":["Treatment"],"weight":1,"_version_":1667342288415621120,"score":276.426},{"pmid":32394344,"title":"COVID-19 in people living with human immunodeficiency virus: a case series of 33 patients.","text":["COVID-19 in people living with human immunodeficiency virus: a case series of 33 patients.","INTRODUCTION: Data on people living with human immunodeficiency virus (PLWH) in the current SARS-CoV-2 pandemic are still scarce. This case series of 33 PLWH patients with COVID-19 reveals symptoms and outcome in this special population. METHODS: Retrospective analysis of anonymized data including age, gender, HIV-associated parameters, symptoms, and outcome. RESULTS: Three out of 32 patients with documented outcomes died (9%). 91% of the patients recovered and 76% have been classified as mild cases. All patients were on antiretroviral treatment, of them 22 on tenofovir-containing regimen and 4 on the protease inhibitor darunavir. CONCLUSIONS: This preliminary case series does not support excess morbidity and mortality among symptomatic COVID-19 PLWH and with viral suppression on ART. SARS-CoV-2 infections may occur during boosted darunavir-based and/or on tenofovir-containing ART.","Infection","Harter, Georg","Spinner, Christoph D","Roider, Julia","Bickel, Markus","Krznaric, Ivanka","Grunwald, Stephan","Schabaz, Farhad","Gillor, Daniel","Postel, Nils","Mueller, Matthias C","Muller, Markus","Romer, Katja","Schewe, Knud","Hoffmann, Christian","32394344"],"abstract":["INTRODUCTION: Data on people living with human immunodeficiency virus (PLWH) in the current SARS-CoV-2 pandemic are still scarce. This case series of 33 PLWH patients with COVID-19 reveals symptoms and outcome in this special population. METHODS: Retrospective analysis of anonymized data including age, gender, HIV-associated parameters, symptoms, and outcome. RESULTS: Three out of 32 patients with documented outcomes died (9%). 91% of the patients recovered and 76% have been classified as mild cases. All patients were on antiretroviral treatment, of them 22 on tenofovir-containing regimen and 4 on the protease inhibitor darunavir. CONCLUSIONS: This preliminary case series does not support excess morbidity and mortality among symptomatic COVID-19 PLWH and with viral suppression on ART. SARS-CoV-2 infections may occur during boosted darunavir-based and/or on tenofovir-containing ART."],"journal":"Infection","authors":["Harter, Georg","Spinner, Christoph D","Roider, Julia","Bickel, Markus","Krznaric, Ivanka","Grunwald, Stephan","Schabaz, Farhad","Gillor, Daniel","Postel, Nils","Mueller, Matthias C","Muller, Markus","Romer, Katja","Schewe, Knud","Hoffmann, Christian"],"date":"2020-05-13T11:00:00Z","year":2020,"_id":"32394344","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1007/s15010-020-01438-z","keywords":["aids","antiretroviral therapy","covid-19","hiv infection","sars-cov-2"],"topics":["Treatment"],"weight":1,"_version_":1666627827890388992,"score":270.95712},{"pmid":32297571,"title":"SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and Other Drugs for the Treatment of the New Coronavirus","text":["SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and Other Drugs for the Treatment of the New Coronavirus","Here we report on the most recent updates on experimental drugs successfully em- ployed in the treatment of the disease caused by SARS-CoV-2 coronavirus, also referred to as COVID-19 (COronaVIrus Disease 19). In particular, several cases of recovered patients have been reported after being treated with lopinavir/ritonavir (which is widely used to treat human immunodeficiency virus (HIV) infection) in combination with the anti-flu drug oseltamivir. In addition, remdesivir, which has been previously administered to Ebola virus patients, has also proven effective in the U.S. against coronavirus, while antimalarial chloroquine and hydroxy- chloroquine, favipiravir and co-administered darunavir and umifenovir (in patient therapies) were also recently recorded as having anti-SARS-CoV-2 effects. Since the recoveries/deaths ratio in the last weeks significantly increased, especially in China, it is clear that the experi- mental antiviral therapy, together with the availability of intensive care unit beds in hospitals and rigorous government control measures, all play an important role in dealing with this vi- rus. This also stresses the urgent need for the scientific community to devote its efforts to the development of other more specific antiviral strategies.","Curr Med Chem","Costanzo, Michele","De Giglio, Maria Anna Rachele","Roviello, Giovanni Nicola","32297571"],"abstract":["Here we report on the most recent updates on experimental drugs successfully em- ployed in the treatment of the disease caused by SARS-CoV-2 coronavirus, also referred to as COVID-19 (COronaVIrus Disease 19). In particular, several cases of recovered patients have been reported after being treated with lopinavir/ritonavir (which is widely used to treat human immunodeficiency virus (HIV) infection) in combination with the anti-flu drug oseltamivir. In addition, remdesivir, which has been previously administered to Ebola virus patients, has also proven effective in the U.S. against coronavirus, while antimalarial chloroquine and hydroxy- chloroquine, favipiravir and co-administered darunavir and umifenovir (in patient therapies) were also recently recorded as having anti-SARS-CoV-2 effects. Since the recoveries/deaths ratio in the last weeks significantly increased, especially in China, it is clear that the experi- mental antiviral therapy, together with the availability of intensive care unit beds in hospitals and rigorous government control measures, all play an important role in dealing with this vi- rus. This also stresses the urgent need for the scientific community to devote its efforts to the development of other more specific antiviral strategies."],"journal":"Curr Med Chem","authors":["Costanzo, Michele","De Giglio, Maria Anna Rachele","Roviello, Giovanni Nicola"],"date":"2020-04-17T11:00:00Z","year":2020,"_id":"32297571","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.2174/0929867327666200416131117","keywords":["covid-19","coronavirus","antiviral drugs","hydroxychloroquine","lopinavir","remdesivir","ritonavir.","favipiravir","sars-cov-2"],"locations":["USA","China"],"countries":["United States","China"],"countries_codes":["USA|United States","CHN|China"],"e_drugs":["Hydroxychloroquine","remdesivir","Oseltamivir","lopinavir-ritonavir drug combination","Chloroquine","Darunavir","favipiravir","arbidol"],"topics":["Treatment"],"weight":1,"_version_":1666138493210853377,"score":252.87413},{"pmid":32280433,"pmcid":"PMC7118541","title":"Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model.","text":["Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model.","The infection of a novel coronavirus found in Wuhan of China (SARS-CoV-2) is rapidly spreading, and the incidence rate is increasing worldwide. Due to the lack of effective treatment options for SARS-CoV-2, various strategies are being tested in China, including drug repurposing. In this study, we used our pre-trained deep learning-based drug-target interaction model called Molecule Transformer-Drug Target Interaction (MT-DTI) to identify commercially available drugs that could act on viral proteins of SARS-CoV-2. The result showed that atazanavir, an antiretroviral medication used to treat and prevent the human immunodeficiency virus (HIV), is the best chemical compound, showing an inhibitory potency with Kd of 94.94 nM against the SARS-CoV-2 3C-like proteinase, followed by remdesivir (113.13 nM), efavirenz (199.17 nM), ritonavir (204.05 nM), and dolutegravir (336.91 nM). Interestingly, lopinavir, ritonavir, and darunavir are all designed to target viral proteinases. However, in our prediction, they may also bind to the replication complex components of SARS-CoV-2 with an inhibitory potency with Kd < 1000 nM. In addition, we also found that several antiviral agents, such as Kaletra (lopinavir/ritonavir), could be used for the treatment of SARS-CoV-2. Overall, we suggest that the list of antiviral drugs identified by the MT-DTI model should be considered, when establishing effective treatment strategies for SARS-CoV-2.","Comput Struct Biotechnol J","Beck, Bo Ram","Shin, Bonggun","Choi, Yoonjung","Park, Sungsoo","Kang, Keunsoo","32280433"],"abstract":["The infection of a novel coronavirus found in Wuhan of China (SARS-CoV-2) is rapidly spreading, and the incidence rate is increasing worldwide. Due to the lack of effective treatment options for SARS-CoV-2, various strategies are being tested in China, including drug repurposing. In this study, we used our pre-trained deep learning-based drug-target interaction model called Molecule Transformer-Drug Target Interaction (MT-DTI) to identify commercially available drugs that could act on viral proteins of SARS-CoV-2. The result showed that atazanavir, an antiretroviral medication used to treat and prevent the human immunodeficiency virus (HIV), is the best chemical compound, showing an inhibitory potency with Kd of 94.94 nM against the SARS-CoV-2 3C-like proteinase, followed by remdesivir (113.13 nM), efavirenz (199.17 nM), ritonavir (204.05 nM), and dolutegravir (336.91 nM). Interestingly, lopinavir, ritonavir, and darunavir are all designed to target viral proteinases. However, in our prediction, they may also bind to the replication complex components of SARS-CoV-2 with an inhibitory potency with Kd < 1000 nM. In addition, we also found that several antiviral agents, such as Kaletra (lopinavir/ritonavir), could be used for the treatment of SARS-CoV-2. Overall, we suggest that the list of antiviral drugs identified by the MT-DTI model should be considered, when establishing effective treatment strategies for SARS-CoV-2."],"journal":"Comput Struct Biotechnol J","authors":["Beck, Bo Ram","Shin, Bonggun","Choi, Yoonjung","Park, Sungsoo","Kang, Keunsoo"],"date":"2020-04-14T11:00:00Z","year":2020,"_id":"32280433","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.csbj.2020.03.025","keywords":["atazanavir","covid-19","coronavirus","deep learning","drug repurposing","mt-dti","sars-cov-2"],"locations":["Wuhan","China","China"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["remdesivir","lopinavir-ritonavir drug combination","efavirenz","Lopinavir","Darunavir","Ritonavir","dolutegravir","Atazanavir Sulfate"],"topics":["Treatment"],"weight":1,"_version_":1666138491477557250,"score":229.68053}]}